Welcome to our dedicated page for Corvus Pharmaceuticals news (Ticker: CRVS), a resource for investors and traders seeking the latest updates and insights on Corvus Pharmaceuticals stock.
Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) is a pioneering clinical-stage biopharmaceutical company focused on the development of novel immunotherapies to treat a broad spectrum of cancers and immune diseases. The company's core innovation is the selective inhibition of interleukin-2-inducible T cell kinase (ITK), which plays a crucial role in T cell and natural killer (NK) cell immune functions. Corvus' lead investigational product, soquelitinib (formerly CPI-818), has shown promise in optimizing T cell differentiation and enhancing immune responses against tumors, as well as in the management of autoimmune diseases.
Corvus is advancing soquelitinib through a Phase 3 registrational trial for relapsed peripheral T cell lymphoma (PTCL), an aggressive and typically treatment-resistant form of non-Hodgkin’s lymphoma. The company’s focus on ITK inhibition offers a new therapeutic approach, given the lack of FDA-approved treatments for relapsed PTCL. Soquelitinib has demonstrated the ability to prevent T cell exhaustion and promote the generation of cytotoxic killer T cells, critical in cancer therapy.
In addition, Corvus is investigating soquelitinib for other immune-mediated conditions, including atopic dermatitis. The company recently initiated a randomized, double-blind Phase 1 clinical trial to evaluate soquelitinib in patients with moderate to severe atopic dermatitis, aiming to provide an oral treatment alternative to current injectable biologics.
Other promising candidates in Corvus' pipeline include ciforadenant, an adenosine A2A receptor inhibitor that disables tumors' immune evasion mechanisms, and mupadolimab, a monoclonal antibody targeting CD73. These candidates are being studied for their efficacy in combination therapies for various cancers, including head and neck cancers and non-small cell lung cancer.
Financially, Corvus maintains a strong position, having raised significant capital through direct offerings to support its clinical trials and operational needs. With cash reserves projected to fund operations into late 2025, Corvus is well-positioned to achieve substantial milestones in its clinical programs. The company continues to foster critical partnerships, including collaborations with Angel Pharmaceuticals for the Chinese market.
Latest news highlights Corvus' progress in clinical trials and strategic financing moves, underscoring its commitment to bringing innovative immunotherapies to patients in need. For more information, visit the Corvus Pharmaceuticals website.
Corvus Pharmaceuticals announced a strategic collaboration with Angel Pharmaceuticals, securing a 49.7% equity stake to enhance its oncology pipeline development in China. Angel, a new biopharmaceutical company, aims to address serious diseases and launches with a $41 million financing, valuing it at $106 million. The collaboration allows for the development of three clinical-stage candidates and global BTK inhibitor programs. Clinical trials for these candidates are expected to commence within 12 to 18 months, leveraging a partnership with prominent Chinese investors and a talented local team.
Corvus Pharmaceuticals (CRVS) announced the completion of enrollment for the first three cohorts of its Phase 1 study for CPI-006, a novel immunotherapy targeting COVID-19. The data indicates a dose-response effect with prolonged high titers of SARS-CoV-2 specific antibodies at 56 days in the 1.0 mg/kg cohort. All treated patients showed increased memory B and T cells, and no drug-related safety issues were reported. Final cohort enrollment is underway, and a pivotal study is planned by year-end. Results are expected at the upcoming SITC meeting in November.
Corvus Pharmaceuticals (CRVS) announced new data from its collaboration with Genentech during the ESMO Virtual Congress 2020. The data focuses on ciforadenant combined with atezolizumab for treating non-small cell lung cancer (NSCLC). In a small study, patients showed longer disease control and overall survival compared to chemotherapy. The median overall survival was 11.5 months for the combination group versus 9.4 months for chemotherapy. Safety data indicated fewer adverse events. Corvus aims to advance ciforadenant into pivotal studies for advanced refractory renal cell cancer.
Corvus Pharmaceuticals (NASDAQ: CRVS) announced promising results from its Phase 1 study of CPI-006 as an immunotherapy for COVID-19. Patients in the first two cohorts exhibited significant antibody responses within 7 days, with neutralizing antibody levels rising to >1:200,000 by day 28. All treated patients showed clinical improvement and were discharged without safety issues. The study has enrolled 30 patients, with plans for an FDA meeting to discuss future pivotal studies. CPI-006 aims to activate the immune system potentially offering long-term immunity against SARS-CoV-2.
Corvus Pharmaceuticals (NASDAQ: CRVS) announced its participation in two upcoming investor conferences. The company will present at the HC Wainwright 22nd Annual Investment Conference on September 14, 2020, at 4:00 PM ET, and at the Cantor Virtual Healthcare Conference on September 17, 2020, at 4:40 PM ET. Both presentations will be available via webcast for 90 days on the Corvus website. Corvus is focused on developing innovative therapies for cancer and is currently advancing multiple clinical trials.
Corvus Pharmaceuticals (NASDAQ: CRVS) will present at the 2020 Wedbush PacGrow Healthcare Virtual Conference on August 11 from 2:55-3:25pm ET. A live webcast will be available for 90 days post-event via the Corvus website.
The company is focused on innovative cancer treatments, studying lead candidates CPI-444 and CPI-006 in various clinical trials. Their research also explores CPI-818 for T-cell lymphomas and CPI-006 for COVID-19.
Corvus Pharmaceuticals (NASDAQ: CRVS) reported its Q2 2020 financial results, highlighting progress in its oncology programs, particularly ciforadenant, which showed a 17% objective response rate in a subset of renal cell carcinoma patients. The company plans to discuss a pivotal study with the FDA. Additionally, they initiated a Phase 1 study for CPI-006 targeting COVID-19, with early results indicating a favorable antibody response. Financially, Corvus ended Q2 with $59.3 million in cash, down from $78.0 million at year-end 2019, and reported a net loss of $10.6 million, an improvement from $13.0 million in Q2 2019.
Corvus Pharmaceuticals (NASDAQ: CRVS) announced a conference call on July 30, 2020, at 4:30 pm ET to discuss its business update and second quarter 2020 financial results. The call can be accessed via a toll-free number or by webcast through the investor relations section of their website. Corvus is a clinical-stage biopharmaceutical firm focused on cancer therapies, with key products including ciforadenant, CPI-006, and CPI-818 currently in various clinical trials, including studies for COVID-19 treatment.
Corvus Pharmaceuticals (NASDAQ: CRVS) has initiated a Phase 1 study to assess its novel immunotherapy, CPI-006, for treating COVID-19. The trial aims to enroll up to 30 patients with mild to moderate symptoms, following FDA acceptance of its IND application. CPI-006 has shown promise in activating B cells and inducing an antibody response in previous cancer studies. Early results from a patient with advanced cancer and COVID-19 demonstrated high levels of anti-SARS-CoV-2 antibodies and increased memory B cells post-treatment. Corvus plans to evaluate the efficacy and safety of CPI-006 and may pursue broader studies based on results.
BURLINGAME, Calif., May 13, 2020 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals (NASDAQ: CRVS) announced the upcoming presentation of updated data on the Adenosine Gene Signature as a predictive biomarker for patients treated with ciforadenant, an A2A receptor antagonist. This data will be presented at the ASCO20 Virtual Scientific Program from May 29-31, 2020. Findings from the Phase 1b/2 trial in advanced refractory renal cell cancer indicate that CD68 positive myeloid cells may enhance patient selection. The poster presentation will be available for on-demand viewing starting May 29, 2020.
FAQ
What is the current stock price of Corvus Pharmaceuticals (CRVS)?
What is the market cap of Corvus Pharmaceuticals (CRVS)?
What is Corvus Pharmaceuticals' lead product candidate?
What conditions is Corvus Pharmaceuticals targeting with soquelitinib?
What is the significance of ITK inhibition in Corvus Pharmaceuticals' research?
What other products are in Corvus Pharmaceuticals' pipeline?
What recent financial developments have supported Corvus Pharmaceuticals' research?
What is the background of Corvus Pharmaceuticals?
What partnerships does Corvus Pharmaceuticals have?
How is Corvus Pharmaceuticals addressing the unmet needs in relapsed PTCL?
How is soquelitinib being evaluated for atopic dermatitis?
What makes mupadolimab unique in Corvus Pharmaceuticals' research?
